BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Becton, Dickinson and Company (BDX), LAB21 Limited Partner for Cancer Mutation Testing


10/15/2012 8:52:50 AM

BALTIMORE and CAMBRIDGE, England, Oct. 15, 2012 /PRNewswire/ -- BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Lab21, a global leader in personalized healthcare diagnostics, announced today that they will collaborate to develop oncology assays for the BD MAX fully automated, bench-top molecular system.

Under the terms of the collaboration, Lab21 will develop polymerase chain reaction-based assays on the BD MAX platform for a series of oncology markers. BD will be responsible for manufacturing and commercializing the tests worldwide. The first two assays will be designed to detect mutations in the KRAS and BRAF genes. These initial assays were selected because of their current importance in optimizing the management of cancer patients. The agreement also includes the development of novel nucleic acid extraction procedures from formalin-fixed paraffin-embedded tissue.

The collaboration will develop BD's first offering in personalized cancer diagnostics on the BD MAX system.

"When used in conjunction with other laboratory and clinical information, these assays will provide critical input to support oncologists and their patients in making more informed decisions about their care," said Tom Polen, President, BD Diagnostics Diagnostic Systems.

Graham Mullis, CEO of Lab21, added, "We are pleased to expand our partnership with BD from the detection of Aspergillus species to the broader development and commercialization of important diagnostic markers in the oncology area. Lab21 has significant experience with and proven assay development capability in cancer molecular diagnostics."

Financial terms of the agreement and information regarding additional assays were not disclosed.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

About Lab21
Lab21 is a global leader in personalized healthcare. It provides diagnostic products and services and supports blood bank screening, medical diagnostics and drug discovery. Lab21 customers include international healthcare providers, pharmaceutical and diagnostic companies. The Products division of Lab21 manufactures immunodiagnostic kits and reagents that are distributed internationally and is focused on infectious diseases for the blood-banking and clinical markets. Lab21's clinical services operations has a growing test portfolio providing companion diagnostics and high technology molecular assays. Lab21's corporate offices are based in Cambridge, UK and South Carolina, USA with a GMP manufacturing site in Cambridge and other manufacturing facilities in Newmarket, Camberley and Bridport. Website: www.lab21.com.

BD Contact:

Lab21 Contact:

Jamie Yacco

College Hill

Public Relations

Nicole Yost/Gemma Howe

T: +1 (201) 847-4796

T: +44 (0) 20 7457 2020

Jamie_Yacco@bd.com

Lab21@collegehill.com

SOURCE BD-Becton Dickinson


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->